SAB Biotherapeutics is advancing a new class of immunotherapies with targeted, fully human polyclonal antibodies for the treatment of Covid-19, diabetes, organ transplant & flu.

Pharmaceutical

SAB Biotherapeutics

Eddie J. Sullivan

Angela Parizek

Russell P. Beyer, MBA, CMA

Melissa Ullerich

Jacob Spade

Dr. Carlos Carrillo, MS, PhD.

Alexandra Kropotova

Christoph Bausch

The board of directors at SAB Biotherapeutics has a long history of experience in the pharmaceutical industry. The current CEO, for example, has served as the CEO of Big Cypress Acquisition Corp. and as the Executive Chairman of Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, Inc. In addition, the Managing Member of The Reich Group also sits on the board. All members of the board have extensive experience in the pharmaceutical industry and hold degrees in Molecular Biology from Clark University.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at SAB Biotherapeutics

Leadership Team

CEO and Executive Team